Standalone & Consolidated Financial Results, Limited Review Report for June 30, 2016
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Consolidated Financial Results for the period ended June 30, 20163. Standalone Limited Review for the period ended June 30, 20164. Consolidated Limited Review for the period ended June 30, 2016 Successful US FDA Inspection at Alkem's Bioequivalence Facility at Taloja
Alkem Laboratories Ltd has informed BSE regarding a Press Release dated August 11, 2016 titled "Successful US FDA Inspection at Alkem's Bioequivalence Facility at Taloja". AGM on Sep 02, 2016
Alkem Laboratories Ltd has informed BSE that the 42nd Annual General Meeting (AGM) of the Company will be held on September 02, 2016. Intimation of Conference Call on Q1FY17 Results
Alkem Laboratories Ltd has informed BSE regarding "Intimation of Conference Call on Q1FY17 Results". Board Meeting Intimation for Results
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on August 12, 2016, inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2016. Shareholding for the Period Ended June 30, 2016
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Alkem Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Closure of Trading Window
Alkem Laboratories Ltd has informed BSE that in terms of Companys Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from June 29, 2016 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended June 30, 2016 are communicated to the Stock Exchanges. Updates
Alkem Laboratories Ltd has informed BSE regarding in relation to certain restructuring of responsibilities between the senior management of the Company.The Joint Managing Directors and Executive Director would be responsible for the following functional areas of the Companys business:- Mr. Dhananjay Kumar Singh, Joint Managing Director, shall be responsible for specific Domestic Business units focusing on Acute and Chronic Therapies... Update on Article appearing on the website of European Medicines Agency (EMA)
Alkem Laboratories Ltd has informed BSE regarding "Update on Article appearing on the website of European Medicines Agency (EMA)".